Can CAR-T cells beat HIV? tiny trial aims for functional cure

NCT ID NCT06880380

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether a patient's own immune cells, modified to target HIV (called CAR-T cells), can help control the virus without daily medication. Only 3 people with well-controlled HIV will receive the treatment. The main goal is to check safety, but researchers will also monitor HIV levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells (a type of immune cell modified to target HIV)
What this could lead to: If it works, this could point toward a functional cure for HIV, meaning the virus is controlled without lifelong medication.
What could go wrong: This is a very early Phase 1 trial with only 3 participants, so safety and effectiveness are unknown. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV-INFECTED INDIVIDUALS

Contacts and locations

Locations

Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology), Tianjin, 300020
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.